Navigation Links
NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
Date:10/15/2008

to new understanding of these conditions and improved criteria for their diagnosis and treatment, who will be awarded the Ruane Prize for Outstanding Achievement in Child and Adolescent Psychiatric Research;
  • Eric J. Nestler, M.D., Ph.D., Mount Sinai Medical Center, whose basic research studies in animal models have elucidated fundamental processes in brain development and disorders such as depression and drug abuse, who will receive the Goldman-Rakic Prize for Outstanding Achievement in Cognitive Neuroscience; and
  • Angus W. MacDonald, III, Ph.D., of the University of Minnesota, an early-career scientist who is conducting promising research on the genetic and neural causes of schizophrenia, who will be awarded the Sidney R. Baer, Jr. Prize for Schizophrenia Research.

NARSAD began awarding prizes in 1987, with the introduction of the Lieber Prize, and over the years added the other prizes as a way to recognize those who have made outstanding contributions to the advancement of brain science and the improvement of treatment options for patients.

Previous winners of NARSAD's Lieber Prize include two scientists who subsequently received the Nobel Prize for Medicine or Physiology in 2000: Arvid Carlsson, M.D., of Gothenberg University in Sweden (Lieber Prize, 1994) and Paul Greengard, Ph.D., of Rockefeller University (Lieber Prize, 1996).

Since NARSAD began funding research in 1987, it has distributed more than $238 million in grants to over 2,700 scientists at 431 universities, medical centers and research institutes in the United States and 27 other countries. In 2008 alone, NARSAD administered a record level of grants, supporting 799 scientists who are conducting clinical and basic research relating to depression, anxiety disorders, including PTSD and OCD, bipolar disorder, schizophrenia, childhood mental disorders, including autism and ADHD, and many other conditions.

Preceding the awards gala on
'/>"/>

Contact: Kristen Simone
ksimone@narsad.org
516-829-0091
NARSAD, The Mental Health Research Association
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
2. At Boston symposium, NARSAD researchers report on genes and family traits
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. LaserCard Corporation Announces Expansion of Middle East Project
5. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
6. Balzan Foundation announces 2007 winners
7. The American Society of Plant Biologists announces 2007 awards
8. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
9. NIST announces 56 new awards for innovative technology research and development
10. Titanium Group Announces Contract With Haitong Securities
11. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2